Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) Receives Clinical Trial Approval for Innovative Drug BIOS-0625 Tablets

Hangzhou Bio-Sincerity Pharma-Tech Drops 9.03%, IPO in 2021 Peaked with 1.2 Billion Yuan Overfunding

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd. (301096.SZ) Reports Q3 Results with Net Profit Decline of 95.68%

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ): Innovative Drug BIOS-0623-Z4 Tablets Receives Clinical Trial Approval

Hong Kong Stocks Movement | XTALPI (02228) Surges Over 8% Again on AI Drug Development Partnership with Hangzhou Bio-Sincerity and Strategic Talks with China Merchants Group

Hong Kong Stocks Movement | XTALPI (02228) Surged Nearly 7% in Morning Trading as Company Signs Cooperation Agreement with Hangzhou Bio-Sincerity Pharma-Tech for Joint AI Drug Development

Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) Subsidiary Hangzhou Mipeng to Invest 15 Million Yuan in Partnership Enterprise, Focusing on Biomedicine and Hard Technology Strategic Emerging Industries

September 11 Holdings Update Summary: Hangzhou Bio-Sincerity Pharma-Tech Increases Position While 26 Stocks Including Shanghai New Centurion Network Show Reductions

Hangzhou Bio-Sincerity Pharma-Tech Records Single Block Trade on August 21 with Total Value of 16.445 Million Yuan at 0.00% Premium

BaiCheng Pharma (301096.SZ) Forecasts H1 Net Profit of RMB 0-6 Million, Plunging 95.53%-100% YoY

Baicheng Medicine (301096.SZ) Forecasts H1 Net Profit Plunge to 0-6 Million Yuan, Down 95.53%-100%